ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,916Medicare Part D Prescriptions Filled, Including Refills

Rank: 58 out of 617

$456K Total Retail Price of All Prescriptions

Rank: 121 out of 617

373 Patients Receiving at Least One Drug in Part D
93%Patients 65 Years and Older
37% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 373 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

12% of this provider’s 373 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

1% of this provider’s 11,329 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$38 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

32 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
FUROSEMIDE 534 510 1 4
SIMVASTATIN 531 480 2 2
LEVOTHYROXINE SODIUM 458 446 3 1
LISINOPRIL 457 443 4 5
METOPROLOL SUCCINATE 431 414 5 12
AMLODIPINE BESYLATE 429 421 6 6
WARFARIN SODIUM 425 418 7 7
PRAVASTATIN SODIUM 352 344 8 21
POTASSIUM CHLORIDE 349 348 9 10
OMEPRAZOLE 321 321 10 3
METOPROLOL TARTRATE 266 254 11 11
CITALOPRAM HBR 257 244 12 18
METFORMIN HCL 240 216 13 9
HYDROCODONE-ACETAMINOPHEN 228 218 S3 14 8
LISINOPRIL-HYDROCHLOROTHIAZIDE 197 171 15 29
ATORVASTATIN CALCIUM 183 176 16 14
DONEPEZIL HCL 173 161 17 30
TRAZODONE HCL 169 160 18 51
NAMENDA 144 132 19 35
CARVEDILOL 143 143 20 19
HYDROCHLOROTHIAZIDE 131 130 21 13
SERTRALINE HCL 131 127 21 20
FENTANYL 124 124 S2 23 45
ATENOLOL 115 114 24 17
LOSARTAN-HYDROCHLOROTHIAZIDE 107 96 25 46
ALENDRONATE SODIUM 107 107 25 25
TRAMADOL HCL 104 103 27 15
LOSARTAN POTASSIUM 103 103 28 22
TAMSULOSIN HCL 103 93 28 26
MELOXICAM 93 87 30 24
LANTUS 92 85 31 39
PAROXETINE HCL 89 89 32 62
GLIPIZIDE XL 87 71 33 147
PREDNISONE 86 85 34 31
ALLOPURINOL 83 80 35 27
SPIRIVA 82 74 36 61
FINASTERIDE 77 77 37 104
RANITIDINE HCL 71 71 38 40
BUSPIRONE HCL 70 70 39 131
GABAPENTIN 66 64 40 16
QUETIAPINE FUMARATE 64 55 41 78
SPIRONOLACTONE-HCTZ 62 62 42 189
ISOSORBIDE MONONITRATE ER 62 62 42 52
DIGOXIN 58 56 44 48
ZOLPIDEM TARTRATE 56 43 45 23
ADVAIR DISKUS 55 52 46 38
LACTULOSE 52 52 47 179
DIOVAN 52 52 47 41
GLIPIZIDE 50 49 49 82
GLIMEPIRIDE 50 50 49 33
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 17, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.